Search

Your search keyword '"Wedemeyer H"' showing total 2,214 results

Search Constraints

Start Over You searched for: Author "Wedemeyer H" Remove constraint Author: "Wedemeyer H"
2,214 results on '"Wedemeyer H"'

Search Results

1. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

3. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

8. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

11. A global research priority agenda to advance public health responses to fatty liver disease

12. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

14. HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY

19. Nicht-alkoholische Fettlebererkrankung (NAFLD) in Deutschland: Baseline-Charakteristika von Patienten aus dem Deutschen NAFLD-Register

21. Die Anlage eines transjugulären intrahepatischen portosystemischen Shunts bei Patient:innen mit dekompensierter Leberzirrhose ist mit einer signifikanten Verbesserung der Lebensqualität assoziiert

22. Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness

23. Global multi-stakeholder endorsement of the MAFLD definition

25. Reverse inflammaging: Long-term effects of HCV cure on biological age.

26. Virale Infektionen bei Lebertransplantierten

27. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data

28. Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

29. Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis

32. Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe

34. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.

36. Hepatitis

37. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts

38. Global multi-stakeholder endorsement of the MAFLD definition

39. Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis

40. Global multi-stakeholder endorsement of the MAFLD definition

41. S3 Guideline: Diagnosis and Therapy of Biliary Carcinoma Short Version 2.00-June 2021, AWMF Register Number: 032-053OL

42. S3-Guideline - Diagnosis and Therapy of Biliary Carcinoma

44. Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry

49. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)

50. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome

Catalog

Books, media, physical & digital resources